AIBotics Ushers in a New Era as Intelligent Service Robotics Arrive in Tel Aviv, Redefining Human-Machine Interaction
Rhea-AI Summary
AIBotics (OTC: AIBT) announced the arrival and immediate deployment of its first shipment of KEENON service robots in Tel Aviv, marking the company’s entry into the Middle East market on Dec. 7, 2025. The shipment follows a September purchase agreement and targets food service, hospitality, retail, logistics, and healthcare to help address local labor shortages.
The company plans to monitor throughput, reliability, and customer satisfaction during initial deployments, pursue a strategic partnership with a publicly traded Israeli company this week, and later introduce KEENON’s next‑generation XMAN humanoid series. AIBotics and KEENON will exhibit at CES Jan. 2026.
Contextual funding data cites Israeli startup raises of approximately US$1.4 billion in Nov. 2025 and US$7.03 billion in the first nine months of 2025.
Positive
- First KEENON service robots shipment arrived in Tel Aviv on Dec. 7, 2025
- Deployment targets labor‑stressed sectors: food service and hospitality
- Signed September purchase agreement to source KEENON service robots
- Planned public showcase at CES Jan. 2026 with KEENON
Negative
- Strategic partnership is not yet finalized; company intends to announce it this week
- Initial roll‑out is pilot‑stage; scaling depends on monitored performance metrics
News Market Reaction 1 Alert
On the day this news was published, EHVVF gained 5.88%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
While AIBT was down -9.52%, several biotech peers showed gains (e.g., LOBEF +8.89%, BPTH +17.81%), suggesting stock-specific pressure rather than a sector-wide move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Oct 23 | LOI & partnership | Positive | +15.4% | LOI to acquire NovaCore and KEENON partnership for Jamaica and CARICOM rollout. |
| Oct 14 | Robots shipment | Positive | +51.5% | Initial fully paid KEENON robot shipment to Israel and Middle East entry. |
| Sep 29 | Strategic partnership | Positive | +16.7% | KEENON partnership for Phill Robot manufacturing and regional distribution rights. |
| Aug 19 | Product pilot launch | Positive | -22.9% | First Phill Robot pilot at a Miami fitness center targeting recovery lounges. |
| Aug 12 | Shareholder update | Neutral | -9.1% | Mid-year update on agentic AI integration, commercialization, and revised platform timeline. |
Positive strategic and partnership news has often led to favorable reactions, but there are instances where upbeat product updates coincided with declines, indicating inconsistent follow-through.
Over the last six months, AIBotics announced multiple strategic steps, including a KEENON partnership on Sep 29, 2025, Middle East robot shipments on Oct 14, 2025, and an LOI to acquire NovaCore Labs on Oct 23, 2025. These news items saw 24-hour moves of +16.67%, +51.52%, and +15.38%, respectively. Earlier in August, the Phill Robot™ pilot and an AI roadmap update were followed by declines of -22.86% and -9.09%. Today’s Tel Aviv deployment update extends the same KEENON and regional expansion narrative.
Market Pulse Summary
The stock moved +5.9% in the session following this news. A strong positive reaction aligns with prior spikes on partnership and deployment news, such as moves of +51.52% and +16.67% after earlier KEENON and regional expansion updates. However, the latest 10-Q highlighted no revenue, ongoing net losses, and a working capital deficit of $4,661,176, alongside heavy reliance on equity issuance and defaulted convertible notes. Any sharp rally would have needed to be weighed against these balance sheet pressures when assessing durability.
Key Terms
autonomous robotics technical
humanoid robot technical
bipedal humanoid robot technical
visual-language-action (vla) model technical
executive order regulatory
working capital deficit financial
stockholders’ deficit financial
convertible notes financial
AI-generated analysis. Not financial advice.
With autonomous robotics now operating in Silicon Wadi and global momentum accelerating, including reports of a potential U.S. robotics executive order from President Trump, AIBotics is seeking a university partner to help advance the XMAN Humanoid and shape the next chapter of intelligent automation
MIAMI, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Aibotics, Inc. (OTC: AIBT) (“AIBotics” or the “Company”), a developer and integrator of AI- and robotics-enhanced technologies and a subsidiary of Ehave, Inc. (OTC: EHVVF), today announced the arrival of the first shipment of service robots from KEENON Robotics in Tel Aviv, Israel. This initial shipment of service robots marked the Company's official entry into the Middle East market. AIBotics began delivery of the robots on Dec. 7, 2025, with deployment following immediately. AIBotics intends to announce a strategic partnership this week with a publicly traded company based in Israel.
The shipment follows the September purchase agreement under which AIBotics secured KEENON’s service robots to address labor shortages in industries such as food service, hospitality, retail, logistics, and healthcare. With labor supply constrained and demand rising, particularly in post-ceasefire Israel, AIBotics believes the robots will help alleviate staffing pressures and support efficient, uninterrupted operations across multiple service sectors.
Recent data confirms a surge in investment in Israel’s tech and startup ecosystem: Israeli startups raised approximately US
“With KEENON’s robots arriving in Tel Aviv this week, AIBotics is proud to deliver immediate solutions to workforce shortages across key industries,” said Ben Kaplan, CEO of AIBotics. “Our goal is to support Israel’s economic recovery and growth by deploying advanced robotics that enhance efficiency, reduce labor constraints, and enable businesses to scale without sacrificing service quality.”
The initial deployment will focus on delivery robots in the food service and hospitality sectors. AIBotics and KEENON will closely monitor performance metrics, including throughput, reliability, and customer satisfaction, to guide future scaling.
Looking ahead, AIBotics plans to roll out KEENON's next-generation humanoid service robots — the "XMAN" series. The Company views humanoid robots as the next chapter in automation: fully adaptable, multi-task capable units designed to operate in complex, dynamic environments common to retail, hospitality, and urban service infrastructure. KEENON recently unveiled the XMAN-F1, a bipedal humanoid robot built on its Visual-Language-Action (VLA) model for versatile service applications.
The timing of this launch is particularly significant, as regional labor shortages and war-related costs are challenging many businesses in Israel. By offering advanced robotics as an alternative to traditional labor, AIBotics aims to help local companies mitigate staffing constraints, maintain operational continuity, and adapt to evolving economic conditions.
Support for robotics is gaining national attention, led by President Trump’s administration, which is now prioritizing robotics and advanced manufacturing as the next phase of America’s AI strategy. The administration is exploring new federal initiatives — including a potential executive order and dedicated working groups — to accelerate adoption and strengthen U.S. competitiveness against countries like China, where industrial robot deployment is already significantly higher. This policy shift reflects a broader global trend toward automation as businesses respond to labor shortages, rising operating costs, and growing demand for intelligent robotics solutions.
Representatives of AIBotics will attend the 2026 Consumer Electronics Show (CES) in Las Vegas in January, alongside KEENON Robotics. CES, the premier global event for consumer electronics and emerging technology, provides a platform for AIBotics to showcase its service robots and next-generation XMAN humanoids to investors, technology buyers, media, and global partners. The Company invites stakeholders to visit its booth and explore how AIBotics aims to lead the next wave of automation and intelligent robotics adoption worldwide.
About AIBotics
AIBotics, Inc. develops and manages AI- and robotics-enhanced technologies designed to solve real-world challenges. Its flagship product, the Phill Robot™, is an AI-powered massage robot that delivers spa-quality recovery with IoT integration. The Company is also focused on the next generation of artificial intelligence, systems capable of making independent decisions, managing complex tasks, and achieving outcomes without direct human input. To accelerate this vision, AIBotics has partnered to co-develop a next-generation autonomous operating platform.
Blending hardware expertise with a growing AI software stack, AIBotics is positioning itself as a leader in personal robotics, healthcare, wellness, and hospitality. The Company is expanding e-commerce distribution and pilot programs for Phill while also investing in R&D for its intelligent assistant platform.
For more information on AIBotics, visit www.aibotics.ai
Forward-Looking Statement Disclaimer
This press release contains “forward-looking statements” within the meaning of applicable securities legislation. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are based on certain assumptions, opinions and estimates of management and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements: (i) the initiation, timing, progress and results of the Company’s research, manufacturing and other development efforts; (ii) the Company’s ability to advance its products to successfully complete development and commercialization; (iii) the manufacturing, development, commercialization, and market acceptance of the Company’s products; (iv) the lack of sufficient funding to finance the product development and business operations; (v) competitive companies and technologies within the Company’s industry and introduction of competing products; (vi) the Company’s ability to establish and maintain corporate collaborations; (vii) loss of key management personnel; (viii) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its products and its ability to operate its business without infringing the intellectual property rights of others; (ix) potential failure to comply with applicable health information privacy and security laws and other state and federal privacy and security laws; and (x) the difficulty of predicting actions of the U.S. Food and Drug Administration and its regulations. All forward-looking statements included in this press release are made only as of the date of this press release. The Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events, or otherwise, except as required by applicable law.
For Media and Investor Relations, please contact:
David L. Kugelman
(866) 692-6847 Toll Free - U.S. & Canada
(404) 281-8556 Mobile and WhatsApp
Email: dk@atlcp.com